Glax­o­SmithK­line of­fers fill-fin­ish ca­pac­i­ty to No­vavax for UK sup­ply of Covid-19 vac­cine

UK drug­mak­er Glax­o­SmithK­line has tak­en a broad re­sponse to the Covid-19 pan­dem­ic, work­ing on both vac­cines and ther­a­peu­tics. So far, that strat­e­gy hasn’t churned out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.